STOCK TITAN

Krystal Biotech, Inc. - $KRYS STOCK NEWS

Welcome to our dedicated page for Krystal Biotech news (Ticker: $KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Krystal Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Krystal Biotech's position in the market.

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan will participate in a fireside chat at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
conferences
-
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, announced its participation in the American Thoracic Society (ATS) 2024 International Conference from May 17-22 in San Diego, CA. The company will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408. Both are modified, replication-defective, non-integrating HSV-1 vectors designed for inhaled lung delivery via nebulization. KB407 aims to treat cystic fibrosis, while KB408 targets alpha-1 antitrypsin deficiency. Data on these candidates will be shared, including insights from ongoing Phase 1 studies. Poster presentations by Dr. Sara Artusi will provide further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
conferences
-
Rhea-AI Summary

Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the BofA Securities 2024 Health Care Conference where Chairman and CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings. The webcast of the presentation will be available on the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences
Rhea-AI Summary

Krystal Biotech, Inc. reported $45.3 million in net product revenue for 1Q 2024. The company is focused on delivering genetic medicines for rare diseases like Dystrophic Epidermolysis Bullosa. With a strong financial position and positive performance in clinical trials, Krystal Biotech is poised for growth. Key developments include progress with VYJUVEK, successful clinical studies in Japan, and ongoing trials for cystic fibrosis and alpha-1 antitrypsin deficiency treatments. The company also received FDA Fast Track Designation for inhaled KB707 for lung tumors. Financially, the company recorded $622.3 million in cash and investments with a net income of $0.9 million for 1Q 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
-
Rhea-AI Summary

Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences
-
Rhea-AI Summary
Krystal Biotech, a commercial-stage biotechnology company, will report its first quarter 2024 financial results on May 6, 2024. The Company's management will host a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences earnings
Rhea-AI Summary
Krystal Biotech announced the dosing of the first patient in a Phase 1 clinical trial for inhaled KB707, a therapy for locally advanced or metastatic solid tumors of the lung. This therapy has the potential to expand the clinical utility of cytokine therapy for difficult-to-treat tumors. The company also received Fast Track Designations for inhaled and intratumoral KB707 from the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) presents new preclinical data on intratumoral delivery of IL-12 and IL-2, showing enhanced local and systemic effector T-cell responses in a cold tumor preclinical model at AACR 2024 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) will participate in the TD Cowen 44th Annual Health Care Conference in Boston. Chairman and CEO Krish S. Krishnan will host a fireside chat and investor meetings. A webcast of the presentation will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
Rhea-AI Summary
Krystal Biotech reports strong financial results with $42.1M in net product revenue in 4Q and $50.7M for the year, FDA alignment for B-VEC eyedrop formulation, and initiation of Phase 1 KB408 trial for AATD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.02%
Tags
Krystal Biotech, Inc.

Nasdaq:KRYS

KRYS Rankings

KRYS Stock Data

5.08B
20.55M
12.91%
89.03%
7.62%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
PITTSBURGH